Pre-order Enquiry
Request Free Sample
Catheter-Related Bloodstream Infections (CRBSIs)- Epidemiology Forecast-2028
SKU ID : DEL-14679808 | Publishing Date : 01-Sep-2019 | No. of pages : 100
Request Sample
Request Customization
Check DiscountsDetailed TOC of Catheter-Related Bloodstream Infections (CRBSIs)- Epidemiology Forecast-2028
1. Key Insights2. Catheter-Related Blood Stream Infection (CRBSI) Epidemiology Overview at a Glance
2.1. Total Epidemiology Distribution of CRBSI in 2017
2.2. Total Epidemiology Distribution of CRBSI in 2028
3. Catheter-Related Bloodstream Infection (CRBSI): Disease Background and Overview
3.1. Introduction
3.2. Difference between CLABSI and CRBSI
3.3. Causes of Catheter-Related Bloodstream Infection (CRBSI)
3.3.1. Micro-organisms
3.3.2. Intravascular Devices
3.4. Risk Factor Associated with Catheter-Related Bloodstream Infection (CRBSI)
3.5. Pathogenesis of Catheter-Related Bloodstream Infection (CRBSI)
3.6. Diagnosis of Catheter-Related Bloodstream Infection (CRBSI)
3.7. Diagnosis Guidelines Catheter-Related Bloodstream Infection (CRBSI)
3.7.1. Infectious Diseases Society of America (IDSA) Guidelines for CRBSI
3.7.2. Spanish Society of Infectious Diseases and Clinical Microbiology and (SEIMC) and the Spanish Society of Intensive and Critical Care Medicine and Coronary Units (SEMICYUC)
3.7.3. British Intestinal Failure Alliance (BIFA):
3.7.4. European Renal Best Practice (ERBP) Recommendations for Diagnosis of CRBSIs
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Incident Population of CRBSI in the 7MM
4.3. Total Diagnosed Incident Population of CRBSI in the 7MM
4.4. Diagnosed Incidence of CRBSI by Causative Pathogens in the 7MM
4.5. Some KOL Insights
5. United States Epidemiology
5.1. Assumptions and Rationale
5.2. Total Incident Population of CRBSI in the United States
5.3. Total Diagnosed Incident Population of CRBSI in the United States
5.4. Diagnosed Incidence of CRBSI by Causative Pathogens in the United States
6. EU5 Epidemiology
6.1. Germany Epidemiology
6.1.1. Assumptions and Rationale
6.1.2. Total Incident Population of CRBSI in Germany
6.1.3. Total Diagnosed Incident Population of CRBSI in Germany
6.1.4. Diagnosed Incidence of CRBSI by Causative Pathogens in Germany
6.2. France Epidemiology
6.2.1. Assumptions and rationale
6.2.2. Total Incident Population of CRBSI in France
6.2.3. Total Diagnosed Incident Population of CRBSI in France
6.2.4. Diagnosed Incidence of CRBSI by Causative Pathogens in France
6.3. Italy Epidemiology
6.3.1. Assumptions and Rationale
6.3.2. Total Incident Population of CRBSI in Italy
6.3.3. Total Diagnosed Incident Population of CRBSI in Italy
6.3.4. Diagnosed Incidence of CRBSI by Causative Pathogens in Italy
6.4. Spain Epidemiology
6.4.1. Assumptions and Rationale
6.4.2. Total Incident Population of CRBSI in Spain
6.4.3. Total Diagnosed Incident Population of CRBSI in Spain
6.4.4. Diagnosed Incidence of CRBSI by Causative Pathogens in Spain
6.5. United Kingdom Epidemiology
6.5.1. Assumptions and Rationale
6.5.2. Total Incident Population of CRBSI in the United Kingdom
6.5.3. Total Diagnosed Incident Population of CRBSI in the United Kingdom
6.5.4. Diagnosed Incidence of CRBSI by Causative Pathogens in the United Kingdom
7. Japan Epidemiology
7.1. Assumptions and Rationale
7.2. Total Incident Population of CRBSI in Japan
7.3. Total Diagnosed Incident Population of CRBSI in Japan
7.4. Diagnosed Incidence of CRBSI by Causative Pathogens in Japan
8. Appendix
8.1. Report Methodology
9. DelveInsight Capabilities
10. Disclaimer
11. About DelveInsight
List of Figures, Tables and Charts Available in Catheter-Related Bloodstream Infections (CRBSIs)- Epidemiology Forecast-2028
TABLE 1: TERMINOLOGY: CLABSI OR CRBSITABLE 2: VARIOUS RISK FACTORS OF CRBSI
TABLE 3: TOTAL INCIDENT POPULATION OF CRBSI IN THE 7MM (2017–2028)
TABLE 4: TOTAL DIAGNOSED INCIDENT POPULATION OF CRBSI IN THE 7MM (2017–2028)
TABLE 5: DIAGNOSED INCIDENCE OF CRBSI BY CAUSATIVE PATHOGENS IN THE 7MM (2017–2028)
TABLE 6: TOTAL INCIDENT POPULATION OF CRBSI IN THE US (2017–2028)
TABLE 7: TOTAL DIAGNOSED INCIDENT POPULATION OF CRBSI IN THE US (2017–2028)
TABLE 8: DIAGNOSED INCIDENCE OF CRBSI BY CAUSATIVE PATHOGENS IN THE US (2017–2028)
TABLE 9: TOTAL INCIDENT POPULATION OF CRBSI IN GERMANY (2017–2028)
TABLE 10: TOTAL DIAGNOSED INCIDENT POPULATION OF CRBSI IN GERMANY (2017–2028)
TABLE 11: DIAGNOSED INCIDENCE OF CRBSI BY CAUSATIVE PATHOGENS IN GERMANY (2017–2028)
TABLE 12: TOTAL INCIDENT POPULATION OF CRBSI IN FRANCE (2017–2028)
TABLE 13: TOTAL DIAGNOSED INCIDENT POPULATION OF CRBSI IN FRANCE (2017–2028)
TABLE 14: DIAGNOSED INCIDENCE OF CRBSI BY CAUSATIVE PATHOGENS IN FRANCE (2017–2028)
TABLE 15: TOTAL INCIDENT POPULATION OF CRBSI IN ITALY (2017–2028)
TABLE 16: TOTAL DIAGNOSED INCIDENT POPULATION OF CRBSI IN ITALY (2017–2028)
TABLE 17: DIAGNOSED INCIDENCE OF CRBSI BY CAUSATIVE PATHOGENS IN ITALY (2017–2028)
TABLE 18: TOTAL INCIDENT POPULATION OF CRBSI IN SPAIN (2017–2028)
TABLE 19: TOTAL DIAGNOSED INCIDENT POPULATION OF CRBSI IN SPAIN (2017–2028)
TABLE 20: DIAGNOSED INCIDENCE OF CRBSI BY CAUSATIVE PATHOGENS IN SPAIN (2017–2028)
TABLE 21: TOTAL INCIDENT POPULATION OF CRBSI IN THE UK (2017–2028)
TABLE 22: TOTAL DIAGNOSED INCIDENT POPULATION OF CRBSI IN THE UK (2017–2028)
TABLE 23: DIAGNOSED INCIDENCE OF CRBSI BY CAUSATIVE PATHOGENS IN THE UK (2017–2028)
TABLE 24: TOTAL INCIDENT POPULATION OF CRBSI IN THE JAPAN (2017–2028)
TABLE 25: TOTAL DIAGNOSED INCIDENT POPULATION OF CRBSI IN THE JAPAN (2017–2028)
TABLE 26: DIAGNOSED INCIDENCE OF CRBSI BY CAUSATIVE PATHOGENS IN JAPAN (2017–2028)
Figure 1: Types of Central Venous and Arterial Catheter and their sites of insertion
Figure 2: Important pathogenic determinants of catheter-related infections
Figure 3: Potential sources of infection of a percutaneous intravascular device
Figure 4: Total Incident Population of CRBSI in the 7MM (2017–2028)
Figure 5: Total Diagnosed Incident Population of CRBSI in the 7MM (2017–2028)
Figure 6: Diagnosed Incidence of CRBSI by Causative Pathogens in the 7MM (2017–2028)
Figure 7: Total Incident Population of CRBSI in the US (2017–2028)
Figure 8: Total Diagnosed Incident Population of CRBSI in the US (2017–2028)
Figure 9: Diagnosed Incidence of CRBSI by Causative Pathogens in the US (2017–2028)
Figure 10: Total Incident Population of CRBSI in Germany (2017–2028)
Figure 11: Total Diagnosed Incident Population of CRBSI in Germany (2017–2028)
Figure 12: Diagnosed Incidence of CRBSI by Causative Pathogens in Germany (2017–2028)
Figure 13: Total Incident Population of CRBSI in France (2017–2028)
Figure 14: Total Diagnosed Incident Population of CRBSI in France (2017–2028)
Figure 15: Diagnosed Incidence of CRBSI by Causative Pathogens in France (2017–2028)
Figure 16: Total Incident Population of CRBSI in Italy (2017–2028)
Figure 17: Total Diagnosed Incident Population of CRBSI in Italy (2017–2028)
Figure 18: Diagnosed Incidence of CRBSI by Causative Pathogens in Italy (2017–2028)
Figure 19: Total Incident Population of CRBSI in Spain (2017–2028)
Figure 20: Total Diagnosed Incident Population of CRBSI in Spain (2017–2028)
Figure 21: Diagnosed Incidence of CRBSI by Causative Pathogens in Spain (2017–2028)
Figure 22: Total Incident Population of CRBSI in the United Kingdom (2017–2028)
Figure 23: Total Diagnosed Incident Population of CRBSI in the United Kingdom (2017–2028)
Figure 24: Diagnosed Incidence of CRBSI by Causative Pathogens in the United Kingdom (2017–2028)
Figure 25: Total Incident Population of CRBSI in Japan (2017–2028)
Figure 26: Total Diagnosed Incident Population of CRBSI in Japan (2017–2028)
Figure 27: Diagnosed Incidence of CRBSI by Causative Pathogens in Japan (2017–2028)
